Migratory
发表于 2025-3-23 11:08:33
http://reply.papertrans.cn/88/8743/874248/874248_11.png
外露
发表于 2025-3-23 17:18:32
http://reply.papertrans.cn/88/8743/874248/874248_12.png
jungle
发表于 2025-3-23 18:44:57
http://reply.papertrans.cn/88/8743/874248/874248_13.png
挣扎
发表于 2025-3-24 00:00:22
http://reply.papertrans.cn/88/8743/874248/874248_14.png
Induction
发表于 2025-3-24 04:48:02
Xian-Cheng JiangIntroduces the impacts of sphingomyelin synthase on metabolic disease.Presents the impact of sphingolipid metabolism on lung disease and cancers.Covers sphingolipid metabolism and drug development
zonules
发表于 2025-3-24 08:44:09
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/s/image/874248.jpg
Offstage
发表于 2025-3-24 12:37:16
https://doi.org/10.1007/978-981-19-0394-6Sphingolipid biochemistry; Lipoprotein-sphingolipid; Sphingolipid-related diseases; Sphingolipid biosyn
Nmda-Receptor
发表于 2025-3-24 18:56:02
0065-2598 r studies on metabolic diseases, as well as pharmaceutical research on drug discovery based on sphingolipid de novo synthase.978-981-19-0396-0978-981-19-0394-6Series ISSN 0065-2598 Series E-ISSN 2214-8019
转换
发表于 2025-3-24 19:55:05
http://reply.papertrans.cn/88/8743/874248/874248_19.png
scotoma
发表于 2025-3-25 02:36:53
Serine Palmitoyltransferase Subunit 3 and Metabolic Diseases, active enzyme. Depending on the stoichiometry of the SPTLC2 and SPTLC3 subunits, the spectrum of SPT products varies. While SPTLC1 and SPTLC2 primarily form C. and C. LCBs, the combination of SPTLC1 and SPTLC3 produces a broader spectrum of LCBs. Genetic and population based studies have shown that